Drugs / GM602
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01854294 | Aug 2013 → Apr 2014 | amyotrophic lateral sclerosis | Genervon Biopharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01221246 | Mar 2011 → Jul 2016 | stroke disorder | Genervon Biopharmaceuticals, LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-03-01 | Genervon Biopharmaceuticals, LLC | Results Genervon presented its GM604 Mechanisms of Action at the 29th International Symposium on ALS/MND in Glasgow, UK genervon.com ↗
Early (6 hour) responses included up-regulation of Notch and hedgehog signaling components with increased expression of developmental genes mediating neurogenesis and axon growth. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-03-01 | Genervon Biopharmaceuticals, LLC | Genervon presented its GM604 Mechanisms of Action at the 29th International Symposium on ALS/MND in Glasgow, UK genervon.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GM602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01221246 ↗ |
| Known as | GM604 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01854294 ↗ |
| Modality | Peptide | “GM604 is a regulatory/signaling peptide” NCT01854294 ↗ |
| Route | Intravenous | “GM602 administered intravenously” NCT01221246 ↗ |